WO2009063821A1 - ヘテロアリールオキシキナゾリン誘導体 - Google Patents

ヘテロアリールオキシキナゾリン誘導体 Download PDF

Info

Publication number
WO2009063821A1
WO2009063821A1 PCT/JP2008/070396 JP2008070396W WO2009063821A1 WO 2009063821 A1 WO2009063821 A1 WO 2009063821A1 JP 2008070396 W JP2008070396 W JP 2008070396W WO 2009063821 A1 WO2009063821 A1 WO 2009063821A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
integer
lower alkyl
group
alkyl group
Prior art date
Application number
PCT/JP2008/070396
Other languages
English (en)
French (fr)
Inventor
Masanori Asai
Tomoharu Iino
Takuya Suga
Akio Ohno
Norikazu Ohtake
Original Assignee
Banyu Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharmaceutical Co., Ltd. filed Critical Banyu Pharmaceutical Co., Ltd.
Priority to ES08849029.7T priority Critical patent/ES2493593T3/es
Priority to US12/742,113 priority patent/US8232284B2/en
Priority to EP08849029.7A priority patent/EP2221301B1/en
Priority to AU2008321959A priority patent/AU2008321959B2/en
Priority to CA2705370A priority patent/CA2705370C/en
Priority to JP2009541122A priority patent/JP5301456B2/ja
Publication of WO2009063821A1 publication Critical patent/WO2009063821A1/ja
Priority to US14/021,639 priority patent/US8846700B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本発明は、グルコキナーゼ活性化作用を有することから、糖尿病、肥満症等の治療に有用な式（Ｉ）： （式中、Ａ環は、低級アルキル基等を有していてもよいピラゾリル基等を示し、Ｂ環は、ヘテロアリール基を示し、Ｒは、低級アルキル基等を示し、Ｒ１は、式（ＩＩ-１）： （式中、Ｒ１１及びＲ１２は、それぞれ独立して、水素原子等を示し、ｍは、２乃至６の整数を示す）で表される基等を示し、Ｒ２は、低級アルキル基等を示し、ｒは０乃至３の整数を示し、ｋは０乃至４の整数を示す）で表される化合物又はその薬学的に許容される塩に関する。
PCT/JP2008/070396 2007-11-12 2008-11-10 ヘテロアリールオキシキナゾリン誘導体 WO2009063821A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES08849029.7T ES2493593T3 (es) 2007-11-12 2008-11-10 Derivado de heteroariloxi quinazolina
US12/742,113 US8232284B2 (en) 2007-11-12 2008-11-10 Heteroaryloxy quinazoline derivative
EP08849029.7A EP2221301B1 (en) 2007-11-12 2008-11-10 Heteroaryloxy quinazoline derivative
AU2008321959A AU2008321959B2 (en) 2007-11-12 2008-11-10 Heteroaryloxy quinazoline derivative
CA2705370A CA2705370C (en) 2007-11-12 2008-11-10 Heteroaryloxy quinazoline derivatives
JP2009541122A JP5301456B2 (ja) 2007-11-12 2008-11-10 ヘテロアリールオキシキナゾリン誘導体
US14/021,639 US8846700B2 (en) 2007-11-12 2013-09-09 Heteroaryl quinazoline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007293256 2007-11-12
JP2007-293256 2007-11-12

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/742,113 A-371-Of-International US8232284B2 (en) 2007-11-12 2008-11-10 Heteroaryloxy quinazoline derivative
US74211310A Continuation 2007-11-12 2010-06-17
US13/539,878 Continuation US20120270856A1 (en) 2007-11-12 2012-07-02 Heteroaryloxy quinazoline derivatives

Publications (1)

Publication Number Publication Date
WO2009063821A1 true WO2009063821A1 (ja) 2009-05-22

Family

ID=40638671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070396 WO2009063821A1 (ja) 2007-11-12 2008-11-10 ヘテロアリールオキシキナゾリン誘導体

Country Status (7)

Country Link
US (3) US8232284B2 (ja)
EP (1) EP2221301B1 (ja)
JP (1) JP5301456B2 (ja)
AU (1) AU2008321959B2 (ja)
CA (1) CA2705370C (ja)
ES (1) ES2493593T3 (ja)
WO (1) WO2009063821A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011130459A1 (en) * 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367420B (es) 2013-03-14 2019-08-21 Convergene Llc Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
AU2016361441B2 (en) * 2015-11-25 2021-08-12 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
WO2005090332A1 (ja) 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd 置換キナゾリン又はピリドピリミジン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
KR20050105488A (ko) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
EP1702919B1 (en) 2003-12-29 2012-05-30 Msd K.K. Novel 2-heteroaryl-substituted benzimidazole derivative
EP1810969B1 (en) 2004-11-02 2013-08-07 Msd K.K. Aryloxy-substituted benzimidazole derivatives
AU2006295645B2 (en) 2005-09-30 2011-09-29 Msd K.K. 2-heteroaryl-substituted indole derivative
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
WO2010107610A1 (en) 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
WO2005090332A1 (ja) 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd 置換キナゾリン又はピリドピリミジン誘導体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DIABETES, vol. 45, 1996, pages 1671 - 1677
FERRE T. ET AL.: "Correction of diabetic alterations by glucokinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A, vol. 93, 1996, pages 7225 - 7230
GARFINKEL D. ET AL.: "Computer modeling identifies glucokinase as glucose sensor of pancreatic beta-cells", AMERICAN JOURNAL PHYSIOLOGY, vol. 247, 1984, pages 527 - 536
GLASER B. ET AL.: "Familial hyperinsulinism caused by an activating glucokinase mutation", NEW ENGLAND JOURNAL MEDICINE, vol. 338, 1998, pages 226 - 230
GRUPE A. ET AL.: "Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis", CELL, vol. 83, 1995, pages 69 - 78
MITSUNOBU 0.: "The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products", SYNTHESIS, vol. 1, 1981, pages 1 - 28
VIONNET N. ET AL.: "Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus", NATURE GENETICS, vol. 356, 1992, pages 721 - 722

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011130459A1 (en) * 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
CN102971313A (zh) * 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Also Published As

Publication number Publication date
US8846700B2 (en) 2014-09-30
CA2705370C (en) 2015-10-13
JP5301456B2 (ja) 2013-09-25
US20120270856A1 (en) 2012-10-25
EP2221301A1 (en) 2010-08-25
US20100249146A1 (en) 2010-09-30
EP2221301A4 (en) 2011-09-21
CA2705370A1 (en) 2009-05-22
ES2493593T3 (es) 2014-09-12
AU2008321959A1 (en) 2009-05-22
US20140011801A1 (en) 2014-01-09
JPWO2009063821A1 (ja) 2011-03-31
AU2008321959B2 (en) 2014-02-13
US8232284B2 (en) 2012-07-31
EP2221301B1 (en) 2014-06-04

Similar Documents

Publication Publication Date Title
WO2009063821A1 (ja) ヘテロアリールオキシキナゾリン誘導体
WO2009069736A1 (ja) 含窒素化合物
WO2006112549A8 (ja) 縮合複素環化合物
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
UA97257C2 (en) Indole derivatives
TNSN08407A1 (en) Organic compounds
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2008102749A1 (ja) 複素環化合物
WO2005097129A3 (en) 6-azaindole compound
WO2006134317A8 (en) Oxadiazole derivatives as dgat inhibitors
WO2009020140A1 (ja) アダマンチルウレア誘導体
MX2009006907A (es) Activador de glucocinasa.
WO2008108380A3 (en) Pyrrole compounds
MY163114A (en) Cyclopentylacrylamide derivative
WO2008111473A1 (ja) グルコキナーゼ活性化物質
MY148703A (en) Polycyclic cinnamide derivatives
MX2009003073A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk.
WO2009016462A3 (en) Substituted bicyclolactam compounds
WO2009107850A3 (en) Fused heterocyclic derivative and use thereof
IL191629A0 (en) Tricyclic amide derivatives useful for treating obesity
TW200631951A (en) 1-Substituted-3-(β-D-glycopyranosyl)nitrogen-containing heterocyclic compound and a medical composition containing the same
WO2009057784A1 (ja) 複素環化合物
WO2007087150A3 (en) Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
WO2009041482A1 (ja) アセチレン化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08849029

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008321959

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009541122

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2705370

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008849029

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008321959

Country of ref document: AU

Date of ref document: 20081110

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12742113

Country of ref document: US